These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 2924885)

  • 1. Intermediate-dose (25 mg/m2) intravenous melphalan for patients with multiple myeloma in relapse or refractory to standard treatment.
    Petrucci MT; Avvisati G; Tribalto M; Cantonetti M; Giovangrossi P; Mandelli F
    Eur J Haematol; 1989 Mar; 42(3):233-7. PubMed ID: 2924885
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intermediate-dose (25mg/m2) IV melphalan for multiple myeloma with renal failure.
    Vigneau C; Ardiet C; Bret M; Laville M; Fiere D; Tranchand B; Fouque D
    J Nephrol; 2002; 15(6):684-9. PubMed ID: 12495285
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Single-dose intravenous melphalan in advanced multiple myeloma.
    Bäck H; Lindblad R; Rödjer S; Westin J
    Acta Haematol; 1990; 83(4):183-6. PubMed ID: 2115714
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravenous melphalan and dexamethasone followed by lymphoblastoid alpha interferon in higher risk multiple myeloma patients.
    Petrucci MT; La Verde G; Ribersani M; Avvisati G; Mandelli F
    Leuk Lymphoma; 2000 Sep; 39(1-2):131-8. PubMed ID: 10975391
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Repeat administration of high dose melphalan in relapsed myeloma.
    Mansi JL; Cunningham D; Viner C; Ellis E; Meldrum M; Milan S; Gore M
    Br J Cancer; 1993 Nov; 68(5):983-7. PubMed ID: 8217614
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravenous melphalan, thalidomide and prednisone in refractory and relapsed multiple myeloma.
    Palumbo A; Avonto I; Bruno B; Ambrosini MT; Bringhen S; Cavallo F; Falco P; Boccadoro M
    Eur J Haematol; 2006 Apr; 76(4):273-7. PubMed ID: 16519697
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bortezomib, low-dose intravenous melphalan, and dexamethasone for patients with relapsed multiple myeloma.
    Popat R; Oakervee H; Williams C; Cook M; Craddock C; Basu S; Singer C; Harding S; Foot N; Hallam S; Odeh L; Joel S; Cavenagh J
    Br J Haematol; 2009 Mar; 144(6):887-94. PubMed ID: 19183191
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Melphalan 100 mg/m2 with stem cell support as first relapse treatment is safe and effective for myeloma patients with long remission after autologous stem cell transplantation.
    Blimark C; Veskovski L; Westin J; Rödjer S; Brune M; Hjorth M; Holmberg E; Andersson PO; Mellqvist UH
    Eur J Haematol; 2011 Aug; 87(2):117-22. PubMed ID: 21535157
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Short course intermediate dose intravenous melphalan therapy in myeloma--relation to early emergence of drug resistance (phase II study).
    Sviland L; Leggat H; Harris AL; Bird G; Proctor SJ
    Acta Haematol; 1987; 78(4):233-8. PubMed ID: 3122488
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intermediate dose of intravenous melphalan in advanced multiple myeloma.
    Tsakanikas S; Papanastasiou K; Stamatelou M; Maniatis A
    Oncology; 1991; 48(5):369-71. PubMed ID: 1745483
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interferon-alpha 2b added to melphalan-prednisone for initial and maintenance therapy in multiple myeloma. A randomized, controlled trial. The Nordic Myeloma Study Group.
    Ann Intern Med; 1996 Jan; 124(2):212-22. PubMed ID: 8533996
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multiple myeloma treated with high dose intravenous melphalan.
    Selby PJ; McElwain TJ; Nandi AC; Perren TJ; Powles RL; Tillyer CR; Osborne RJ; Slevin ML; Malpas JS
    Br J Haematol; 1987 May; 66(1):55-62. PubMed ID: 3593657
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The use of intravenous intermediate dose melphalan and dexamethasone as induction treatment in the management of de novo multiple myeloma.
    Schey SA; Kazmi M; Ireland R; Lakhani A
    Eur J Haematol; 1998 Nov; 61(5):306-10. PubMed ID: 9855245
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I/II trial assessing bortezomib and melphalan combination therapy for the treatment of patients with relapsed or refractory multiple myeloma.
    Berenson JR; Yang HH; Sadler K; Jarutirasarn SG; Vescio RA; Mapes R; Purner M; Lee SP; Wilson J; Morrison B; Adams J; Schenkein D; Swift R
    J Clin Oncol; 2006 Feb; 24(6):937-44. PubMed ID: 16418495
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized trial of interferon maintenance in multiple myeloma: a study of the National Cancer Institute of Canada Clinical Trials Group.
    Browman GP; Bergsagel D; Sicheri D; O'Reilly S; Wilson KS; Rubin S; Belch A; Shustik C; Barr R; Walker I
    J Clin Oncol; 1995 Sep; 13(9):2354-60. PubMed ID: 7666094
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modified adriamycin-vincristine-dexamethasone (m-VAD) in primary refractory and relapsed plasma cell myeloma: an NCI (Canada) pilot study. The National Cancer Institute of Canada Clinical Trials Group.
    Browman GP; Belch A; Skillings J; Wilson K; Bergsagel D; Johnston D; Pater JL
    Br J Haematol; 1992 Nov; 82(3):555-9. PubMed ID: 1486035
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multicyclic, dose-intensive chemotherapy supported by hemopoietic progenitors in refractory myeloma patients.
    Palumbo A; Pileri A; Triolo S; Omedè P; Bruno B; Ciravegna G; Galliano M; Frieri R; Boccadoro M
    Bone Marrow Transplant; 1997 Jan; 19(1):23-9. PubMed ID: 9012927
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival.
    Palumbo A; Bringhen S; Larocca A; Rossi D; Di Raimondo F; Magarotto V; Patriarca F; Levi A; Benevolo G; Vincelli ID; Grasso M; Franceschini L; Gottardi D; Zambello R; Montefusco V; Falcone AP; Omedé P; Marasca R; Morabito F; Mina R; Guglielmelli T; Nozzoli C; Passera R; Gaidano G; Offidani M; Ria R; Petrucci MT; Musto P; Boccadoro M; Cavo M
    J Clin Oncol; 2014 Mar; 32(7):634-40. PubMed ID: 24449241
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intermittent high-dose melphalan/prednisone vs continuous low-dose melphalan treatment in multiple myeloma.
    Ahre A; Björkholm M; Mellstedt H; Holm G; Brenning G; Engstedt L; Gahrton G; Hällen J; Johansson B; Johansson SG; Karnström L; Killander A; Lerner R; Lockner D; Lönnqvist B; Simonsson B; Stalfelt AM; Ternstedt B; Wadman B
    Eur J Cancer Clin Oncol; 1983 Apr; 19(4):499-506. PubMed ID: 6345174
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-dose melphalan for multiple myeloma: long-term follow-up data.
    Cunningham D; Paz-Ares L; Gore ME; Malpas J; Hickish T; Nicolson M; Meldrum M; Viner C; Milan S; Selby PJ
    J Clin Oncol; 1994 Apr; 12(4):764-8. PubMed ID: 8151320
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.